DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» BI 224436
BI 224436
The Design, Synthesis and Optimization of Allosteric Hiv-1
Mutational Studies of Novel Screened Molecules Against Wild and Mutated HIV-1 Integrase Using Molecular Docking Studies Pawan Gupta1,2*, Prabha Garg2
Fourth Quarter Product Sales of $2.13 Billion, up 11% Year Over Year
This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
Interbiotech Ritonavir
The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients
Discovery of Novel Integrase Inhibitors Acting Outside the Active Site Through High-Throughput Screening
Hiv Integrase Mechanisms of Resistance to Raltegravir, Elvitegravir, and Dolutegravir Kyla Nicole Ross Wayne State University
The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Hoffmann Rockstroh |
BI 224436 | Medchemexpress
HIV Pipeline 2017: Targets in the HIV Lifecycle Targets in the HIV Lifecycle 1 HIV Attaches to a CD4 Cell
Clinical Pharmacology Related Considerations
Tesi Definitiva DMST Elisa Rita Ceresola
Determinants of the Development and Evolution of HIV-1 Drug Resistance
HIV and HBV What’S Coming Next Moderator: Josep Maria Llibre, Spain
Monoclonal Antibody
J Biol Chem 2019 Oct 11
Top View
Electronic Supplementary Information
CAPITULO 05.Indd
•HCV•TB ABOUT HIV I-BASE
New Drugs Gulick 10.15 UPDATED
Tea Catechin As Antiviral Agent Via Apoptosis Agonist and Triple
HIV/AIDS Presented by America’S Biopharmaceutical Research Companies
(12) United States Patent (10) Patent No.: US 9,708,342 B2 Carra Et Al
Protein-Protein Interaction As a New Strategy to Inhibit HIV-1 Integrase
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
WO 2015/196116 Al 23 December 2015 (23.12.2015) P O P C T
Human Immunodeficiency Virus
Dione Derivatives: Synthesis and Biological Evaluation As Potential HIV-1 Integrase Inhibitors
The Use of Heterocycles As Important Structures in Medicinal Chemistry
Novel Therapeutic Strategies Targeting HIV Integrase Peter K Quashie1,2, Richard D Sloan1 and Mark a Wainberg1,2,3*
De Novo Designed Based Identification of Potential HIV-1 Integrase Inhibitors: a Pharmacoinformatics Study
Progress in HIV-1 Integrase Inhibitors: a Review of Their Chemical Structure Diversity
45PYRAZINO2,1-B1.3OXAZEPINES E. : It
Study on Suitable Analysis Method for HIV-1 Non-Catalytic Integrase Inhibitor